Edgar Filing: ESPERION THERAPEUTICS INC/MI - Form 8-K

ESPERION THERAPEUTICS INC/MI

Form 8-K April 17, 2003

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 17, 2003

ESPERION THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)

Delaware 001-16033 38-3419139

(State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.)

Registrant's telephone number, including area code: (734) 332-0506

- Item 7. Financial Statements and Exhibits.
 - (c) Exhibits.

Exhibit 99.1 Press Release dated April 17, 2003 of Esperion Therapeutics, Inc.

Item 9. Regulation FD Disclosure.

The following is being furnished pursuant to Item 12 of Form 8-K:

On April 17, 2003, Esperion Therapeutics, Inc. issued a press release reporting financial results for the quarter ended March 31, 2003. The press release is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.6 of Form 8-K, the information in this report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the

Edgar Filing: ESPERION THERAPEUTICS INC/MI - Form 8-K

registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ESPERION THERAPEUTICS, INC.

By: /s/ ROGER S. NEWTON

Name: Roger S. Newton, Ph.D

Title: President and Chief Executive Officer

Dated: April 17, 2003

EXHIBIT INDEX

EXHIBIT NO. EXHIBIT DESCRIPTION

Exhibit 99.1 Press Release dated April 17, 2003 of Esperion Therapeutics, Inc.